CCG-232964

• Description :

  CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression[1].

• UNSPSC :

  12352005

• Target :

  Ras; ROCK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ccg-232964.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(O)CCCSC1=NN=C(C2=CC=C(C3CC3)C=C2Cl)O1

• Molecular Formula :

  C15H15ClN2O3S

• Molecular Weight :

  338.81

• References & Citations :

  [1]Kahl, Dylan, et al. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF) /Serum Reponse Factor (SRF) -Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. Journal of Medicinal Chemistry, (), acs.jmedchem.8b01772–.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2349373-70-0]